Fungal infection in heart-lung transplant recipients receiving single-agent prophylaxis with itraconazole

Experimental and Clinical Transplantation

Volumn 9, Issue 6, 2011, Pages 399-404

  Hayes Jr , Don ^a   Ball, Amanda M ^b   Mansour, Heidi M ^a   Martin, Craig A ^a   Flynn, Jeremy D ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Antifungal prophylaxis; Heart transplant; Itraconazole; Lung transplant

Indexed keywords

AMPHOTERICIN B; CASPOFUNGIN; FLUCONAZOLE; ITRACONAZOLE; VORICONAZOLE;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; ASPERGILLUS FUMIGATUS; ASPERGILLUS NIDULANS; ASPERGILLUS TERREUS; CANDIDA ALBICANS; CANDIDA GLABRATA; CARDIOMYOPATHY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CYSTIC FIBROSIS; DRUG TOLERABILITY; FEMALE; GRAFT RECIPIENT; HEART TRANSPLANTATION; HUMAN; INFECTION PREVENTION; LUNG FIBROSIS; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORBIDITY; MUCOR; MYCOSIS; OBSERVATIONAL STUDY; PULMONARY HYPERTENSION; RETROSPECTIVE STUDY;

ACADEMIC MEDICAL CENTERS; ACUTE DISEASE; ADULT; AGED; ANTIFUNGAL AGENTS; FEMALE; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; ITRACONAZOLE; KENTUCKY; LUNG TRANSPLANTATION; MALE; MIDDLE AGED; MYCOSES; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 83455242885     PISSN: 13040855     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Dummer JS, Montero CG, Griffith BP, Hardesty RL, Paradis IL, Ho M. Infections in heart-lung transplant recipients. Transplantation. 1986;41(6):725-729.
2. Dauber JH, Paradis IL, Dummer JS. Infectious complications in pulmonary allograft recipients. Clin Chest Med. 1990;11(2):291-308.
3. Maurer JR, Tullis DE, Grossman RF, Vellend H, Winton TL, Patterson GA. Infectious complications following isolated lung transplantation. Chest. 1992;101(4):1056-1059.
4. Horvath J, Dummer S, Loyd J, Walker B, Merrill WH, Frist WH. Infection in the transplanted and native lung after single lung transplantation. Chest. 1993;104(3):681-685.
5. Kanj SS, Welty-Wolf K, Madden J, et al. Fungal infections in lung and heart-lung transplant recipients. Report of 9 cases and review of the literature. Medicine (Baltimore). 1996;75(3):142-156.
6. Paterson DL, Singh N. Invasive aspergillosis in transplant recipients. Medicine (Baltimore). 1999;78(2):123-138.
7. Mehrad B, Paciocco G, Martinez FJ, Ojo TC, Iannettoni MD, Lynch JP 3rd. Spectrum of Aspergillus infection in lung transplant recipients: case series and review of the literature. Chest. 2001;119(1):169-175.
8. Palmer SM, Drew RH, Whitehouse JD, et al. Safety of aerosolized amphotericin B lipid complex in lung transplant recipients. Transplantation. 2001;72(3):545-548.
9. Singh N, Husain S. Aspergillus infections after lung transplantation: clinical differences in type of transplant and implications for management. J Heart Lung Transplant. 2003;22(3):258-266.
10. Singh N, Paterson DL. Aspergillus infections in transplant recipients. Clin Microbiol Rev. 2005;18(1):44-69.
11. Groetzner J, Kaczmarek I, Wittwer T, et al. Caspofungin as first-line therapy for the treatment of invasive aspergillosis after thoracic organ transplantation. J Heart Lung Transplant. 2008;27(1):1-6.
12. Solé A, Salavert M. Fungal infections after lung transplantation. Transplant Rev (Orlando). 2008;22(2):89-104.
13. Minari A, Husni R, Avery RK, et al. The incidence of invasive aspergillosis among solid organ transplant recipients and implications for prophylaxis in lung transplants. Transpl Infect Dis. 2002;4(4):195-200.
14. Neoh CF, Snell GI, Kotsimbos T, et al. Antifungal prophylaxis in lung transplantation-A world-wide survey. Am J Transplant. 2011;11(2):361-366.
15. Dummer JS, Lazariashvilli N, Barnes J, Ninan M, Milstone AP. A survey of anti-fungal management in lung transplantation. Heart Lung Transplant. 2004;23(12):1376-1381.
16. Muñoz P, Rodríguez C, Bouza E, et al. Risk factors of invasive aspergillosis after heart transplantation: protective role of oral itraconazole prophylaxis. Am J Transplant. 2004;4(4):636-643.
17. Paniagua Martin MJ, Marzoa Rivas R, Barge Caballero E, et al. Efficacy and tolerance of different types of prophylaxis for prevention of early aspergillosis after heart transplantation. Transplant Proc. 2010;42(8):3014-3016.
18. Salavert M. Prophylaxis, pre-emptive or empirical antifungal therapy: which is best in non-lung transplant recipients? Int J Antimicrob Agents. 2008;(32 suppl 2):S149-S153
19. Cadena J, Levine DJ, Angel LF, et al. Antifungal prophylaxis with voriconazole or itraconazole in lung transplant recipients: hepatotoxicity and effectiveness. Am J Transplant. 2009;9(9):2085-2091.
20. Thompson GR 3rd, Cadena J, Patterson TF. Overview of antifungal agents. Clin Chest Med. 2009;30(2):203-215, v
21. Ascioglu S, Rex JH, de Pauw B, et al. Mycoses Study Group of the National Institute of Allergy and Infectious Diseases. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis. 2002;34(1):7-14.
22. Villacian JS, Paya CV. Prevention of infections in solid organ transplant recipients. Transpl Infect Dis. 1999;1(1):50-64.
23. Gavalda J, Len O, San Juan R, et al. Risk factors for invasive aspergillosis in solid-organ transplant recipients: a case-control study. Clin Infect Dis. 2005;41(1):52-59.
24. Muñoz P, Rodríguez C, Bouza E, et al. Risk factors of invasive aspergillosis after heart transplantation: protective role of oral itraconazole prophylaxis. Am J Transplant. 2004;4(4):636-643.
25. Iversen M, Burton CM, Vand S, et al. Aspergillus infection in lung transplant patients: incidence and prognosis. Eur J Clin Microbiol Infect Dis. 2007;26(12):879-886.
26. Gordon SM, Avery RK. Aspergillosis in lung transplantation: incidence, risk factors, and prophylactic strategies. Transpl Infect Dis. 2001;3(3):161-167.
27. Minari A, Husni R, Avery RK, et al. The incidence of invasive aspergillosis among solid organ transplant recipients and implications for prophylaxis in lung transplants. Transpl Infect Dis. 2002;4(4):195-200.
28. Yeldandi V, Laghi F, McCabe MA, et al. Aspergillus and lung transplantation. J Heart Lung Transplant. 1995;14(5):883-890.
29. Montoya JG, Chaparro SV, Celis D, et al. Invasive aspergillosis in the setting of cardiac transplantation. Clin Infect Dis. 2003;(37 suppl 3):S281-S292
30. Solé A, Morant P, Salavert M, Pemán J, Morales P; Valencia Lung Transplant Group. Aspergillus infections in lung transplant recipients: risk factors and outcome. Clin Microbiol Infect. 2005;11(5):359-365.
31. Kubak BM. Fungal infection in lung transplantation. Transpl Infect Dis. 2002;4 (suppl 3):24-31.
32. Rubin RH. Overview: pathogenesis of fungal infections in the organ transplant recipient. Transpl Infect Dis. 2002;(4 suppl 3):12-17.
33. Alexander BD, Tapson VF. Infectious complications of lung transplantation. Transpl Infect Dis. 2001;3(3):128-137.